AIB1 is a predictive factor for tamoxifen response in premenopausal women
نویسندگان
چکیده
منابع مشابه
AIB1 is a predictive factor for tamoxifen response in premenopausal women.
BACKGROUND Clinical trials implicate the estrogen receptor (ER) coactivator amplified in breast cancer 1 (AIB1) to be a prognostic and a treatment-predictive factor, although results are not unanimous. We have further investigated this using a controlled randomised trial of tamoxifen versus control. MATERIALS AND METHODS A total of 564 premenopausal women were entered into a randomised study ...
متن کاملThe role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.
Background The steroid-receptor coactivator amplified in breast cancer one (AIB1) is implicated to be a prognostic factor, although the results are not unanimous. Recently its effect was suggested to be modified by paired box 2 gene product (PAX2). Patients and methods Using immunohistochemistry (IHC) AIB1 and PAX2 were investigated in two cohorts of early breast cancer, including systemically ...
متن کاملOestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
BACKGROUND The oestrogen receptor (ER) co-activator amplified in breast cancer 1 (AIB1) has been suggested as a treatment predictive and prognostic marker in breast cancer. Studies have however not been unanimous. PATIENTS AND METHODS AIB1 protein expression was analysed by immunohistochemistry on tissue micro-arrays with tumour samples from 910 postmenopausal women randomised to tamoxifen tr...
متن کاملTamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women
PURPOSE Tamoxifen is an anti-estrogenic drug that is widely used for endocrine-dependent breast cancer as adjuvant hormonal therapy, and its use has been reported to be frequently associated with high levels of serum estradiol. Since the population of premenopausal women receiving tamoxifen therapy is growing in Japan, we retrospectively analyzed the incidence of ovarian hyperstimulation by tam...
متن کاملE16. Amenorrhoea, aromatase inhibitors, tamoxifen or a combination in premenopausal women
The ovary is the major site of oestrogen production in premenopausal women. Removal of the ovaries in premenopausal patients with breast cancer has long been recognised to potentially alter the course of disease. This procedure leads to a marked reduction in the circulating levels of oestrogen. It has been shown that ovariectomy given as an adjuvant treatment reduces the odds of recurrence or d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2010
ISSN: 0923-7534
DOI: 10.1093/annonc/mdp293